# Pfizer sold nearly $6.4 billion of Vyndamax and related drugs in 2025.

*biotech · news · 2026-04-28 · Reuters*

## Key points

- Pfizer's Vyndamax patent protection in the U.S. is extended until June 1, 2031.
- Previously predicted revenue decline in 2029 for Vyndamax is now expected to be delayed until mid-2031.
- The patent settlements will smooth Pfizer’s late-2020s earnings, compensating for other key drug expirations.
- In 2025, Pfizer sold nearly $6.4 billion of Vyndamax and related ATTR-CM drugs.

**Companies:** Pfizer
**Countries:** United States, India

[Read the full story on Reuters](https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-secures-deals-keep-heart-drug-free-generic-rivals-until-2031-2026-04-28/)

---

Canonical: https://newsio.io/n/f1b88f72-1fcb-4abe-9fb0-00a175c3e0f5/pfizer-sold-nearly-6-4-billion-of-vyndamax-and-related-drugs-in-2025-the-settlem
Summarized by Newsio from Reuters. https://newsio.io/how-it-works